Insider Spends US$301k Buying More Shares In PetMed Express
Insider Spends US$301k Buying More Shares In PetMed Express
Investors who take an interest in PetMed Express, Inc. (NASDAQ:PETS) should definitely note that the Independent Chairman of the Board, Gian Fulgoni, recently paid US$7.34 per share to buy US$301k worth of the stock. That certainly has us anticipating the best, especially since they thusly increased their own holding by 60%, potentially signalling some real optimism.
對PetMed Express, Inc.(納斯達克股票代碼:PETS)感興趣的投資者一定要注意,董事會獨立主席吉安·富爾戈尼最近以每股7.34美元的價格購買了價值30.1萬美元的股票。這無疑使我們對最好的情況充滿期待,尤其是因爲他們因此將自己的持股量增加了60%,這可能預示着一些真正的樂觀情緒。
View our latest analysis for PetMed Express
查看我們對PetMed Express的最新分析
PetMed Express Insider Transactions Over The Last Year
PetMed Express 過去一年的內幕交易
Notably, that recent purchase by Gian Fulgoni is the biggest insider purchase of PetMed Express shares that we've seen in the last year. That means that an insider was happy to buy shares at around the current price of US$7.90. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. We do always like to see insider buying, but it is worth noting if those purchases were made at well below today's share price, as the discount to value may have narrowed with the rising price. In this case we're pleased to report that the insider purchases were made at close to current prices.
值得注意的是,吉安·富爾戈尼最近的收購是我們去年對PetMed Express股票的最大一次內幕收購。這意味着一位內部人士樂於以目前的7.90美元左右的價格購買股票。儘管自收購以來,他們的看法可能發生了變化,但這至少表明他們對公司的未來充滿信心。我們一直希望看到內幕買盤,但值得注意的是,這些收購的價格是否遠低於今天的股價,因爲隨着價格的上漲,價值折扣可能已經縮小。在這種情況下,我們很高興地報告,內幕收購是以接近當前的價格進行的。
In the last twelve months PetMed Express insiders were buying shares, but not selling. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
在過去的十二個月中,PetMed Express內部人士購買了股票,但沒有賣出股票。你可以在下面看到過去 12 個月的內幕交易(公司和個人)的直觀描述。如果你點擊圖表,你可以看到所有的個人交易,包括股價、個人和日期!
![insider-trading-volume](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20231115/0-429e4f704d7d2bb3b46b5fbd03873c04-0-27b20aa56fcecef5f1f5ce5ec70552e2.png/big)
There are always plenty of stocks that insiders are buying. So if that suits your style you could check each stock one by one or you could take a look at this free list of companies. (Hint: insiders have been buying them).
內部人士總是會買入很多股票。因此,如果這適合你的風格,你可以逐一查看每隻股票,也可以看看這份免費的公司清單。(提示:內部人士一直在買入它們)。
Insider Ownership Of PetMed Express
PetMed Express 的內部
For a common shareholder, it is worth checking how many shares are held by company insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. From our data, it seems that PetMed Express insiders own 4.8% of the company, worth about US$7.4m. We do generally prefer see higher levels of insider ownership.
對於普通股股東來說,值得檢查一下公司內部人士持有多少股票。我認爲,如果內部人士擁有該公司的大量股份,這是一個好兆頭。從我們的數據來看,PetMed Express內部人士似乎擁有該公司4.8%的股份,價值約740萬美元。我們通常更願意看到更高的內部所有權水平。
So What Do The PetMed Express Insider Transactions Indicate?
那麼 PetMed Express 內幕交易表明了什麼?
It's certainly positive to see the recent insider purchases. And an analysis of the transactions over the last year also gives us confidence. But we don't feel the same about the fact the company is making losses. While the overall levels of insider ownership are below what we'd like to see, the history of transactions imply that PetMed Express insiders are reasonably well aligned, and optimistic for the future. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. While conducting our analysis, we found that PetMed Express has 1 warning sign and it would be unwise to ignore it.
看到最近的內幕收購無疑是積極的。對去年交易的分析也給了我們信心。但是,我們對公司虧損的事實有不同的看法。儘管內部人所有權的總體水平低於我們希望看到的水平,但交易歷史表明,PetMed Express內部人士相當一致,對未來持樂觀態度。因此,這些內幕交易可以幫助我們建立有關該股的論點,但了解該公司面臨的風險也值得一試。在進行分析時,我們發現PetMed Express有1個警告信號,忽視它是不明智的。
Of course PetMed Express may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
當然,PetMed Express可能不是最值得購買的股票。因此,您可能希望看到這個免費的高質量公司集合。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
就本文而言,內部人士是那些向相關監管機構報告交易的個人。我們目前僅對公開市場交易和直接權益的私人處置進行覈算,但不包括衍生品交易或間接權益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St 的這篇文章本質上是籠統的。我們僅使用公正的方法提供基於歷史數據和分析師預測的評論,我們的文章並非旨在提供財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不會考慮最新的價格敏感型公司公告或定性材料。華爾街只是沒有持有上述任何股票的頭寸。